Oncternal Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Oncternal Therapeutics, Inc. carries a market capitalization of 1.56M, placing it among publicly traded companies globally. Its enterprise value stands at -10.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.56M |
| Enterprise Value | -10.48M |
Share Statistics
Oncternal Therapeutics, Inc. currently has 2.96M shares outstanding.
| Shares Outstanding | 2.96M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | -0.15 |
| P/OCF Ratio | -0.15 |
Financial Position
Oncternal Therapeutics, Inc. maintains a current ratio of 2.39, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.39 |
| Quick Ratio | 2.31 |
| Debt / Equity | 2.09 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -117.61 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Oncternal Therapeutics, Inc.'s stock has declined approximately -95.24729% over the past 52 weeks. The 50-day moving average sits at 0.53, while the 200-day moving average is 3.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | -95.24729% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 3.80 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -35.96M, while operating income came in at -35.96M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -35.96M |
| Pretax Income | -34.57M |
| Net Income | -34.57M |
| EBITDA | -35.96M |
| EBIT | -35.96M |
| Earnings Per Share (EPS) | -11.68 |
Balance Sheet
Oncternal Therapeutics, Inc. holds 14.58M in cash and equivalents against 191,000.00 in total debt, resulting in a net debt position of -13.08M. Total book value stands at -223.19M, with working capital of 8.99M providing operational flexibility.
| Cash & Cash Equivalents | 14.58M |
| Total Debt | 191,000.00 |
| Net Debt | -13.08M |
| Equity (Book Value) | -223.19M |
| Book Value Per Share | -75.41 |
| Working Capital | 8.99M |
Cash Flow
Oncternal Therapeutics, Inc. produced -26.63M in operating cash flow over the past twelve months.
| Operating Cash Flow | -26.63M |
| Capital Expenditures | N/A |
| Free Cash Flow | -26.63M |
| FCF Per Share | -9.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 2.25 |
| FCF Yield | -681.69 |
Stock Splits
Oncternal Therapeutics, Inc.'s most recent stock split took place on January 8, 2024 with a 20:1 split ratio.
| Last Split Date | 1/8/2024 |
| Split Ratio | 20:1 |
Scores
Oncternal Therapeutics, Inc. posts an Altman Z-Score of -26.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -26.58 |